CJC-1295 (no DAC)

Use Promo Code

BUY2GET1CJCNODAC5

or

BUY2GET1CJCNODAC10

Compliance & Disclaimer

• For Research Use Only
• Not FDA or EMA approved for clinical application
• Evidence is limited to preclinical studies; safety and efficacy in humans remain unestablished.

CJC-1295 (No DAC), also known as Modified GRF (1-29), is a synthetic growth hormone-releasing hormone (GHRH) analog designed to mimic the first 29 amino acids of endogenous GHRH while incorporating four strategic amino acid substitutions (positions 2, 8, 15, and 27) for enhanced stability against enzymatic degradation. Unlike the DAC-conjugated version, which binds albumin for prolonged activity, the No DAC variant retains a short half-life (~30 minutes), enabling pulsatile GH release that closely replicates physiological secretion patterns. [oathpeptides.com], [nexusbiolife.com] [hkroids.com], [medicalnewshome.com]

Mechanistic Insights

• GHRH Receptor Activation:
  CJC-1295 No DAC binds to GHRH receptors (GHRH-R) on anterior pituitary somatotroph cells, activating adenylate cyclase, increasing cAMP, and stimulating protein kinase A (PKA) signaling. This cascade triggers growth hormone (GH) secretion, which subsequently elevates insulin-like growth factor 1 (IGF-1) production in the liver and peripheral tissues. [oathpeptides.com], [medicalnewshome.com]

• Short-Acting Profile for Pulsatility:
  The absence of DAC ensures rapid clearance, producing discrete GH pulses rather than sustained elevation. This pulsatile pattern is critical for maintaining receptor sensitivity and mimicking natural endocrine rhythms, making CJC-1295 No DAC ideal for research on circadian GH dynamics and feedback regulation. [hkroids.com], [nexusbiolife.com]

• Structural Modifications:
  Substitutions at key positions confer resistance to dipeptidyl peptidase-IV (DPP-IV) and other proteolytic enzymes, improving stability compared to native GHRH while preserving physiologic signaling kinetics. [oathpeptides.com]

Research Applications

• Endocrine & Metabolic Studies:
  Used to model natural GH pulsatility, CJC-1295 No DAC supports investigations into GH/IGF-1 axis regulation, protein synthesis, and lipid metabolism in controlled experimental settings. [medicalnewshome.com]

• Circadian Rhythm & Sleep Research:
  Its short half-life makes it suitable for studies on sleep-related GH peaks, recovery physiology, and neuroendocrine timing. [hkroids.com]

• Synergistic Protocols:
  Frequently combined with ghrelin receptor agonists (e.g., Ipamorelin) to explore dual-pathway GH stimulation, enabling research into complex neuroendocrine interactions. [uspeptideco.com]

Pharmacokinetics

• Half-life: ~30 minutes (vs. 6–8 days for DAC version)
• Clearance: Rapid, requiring multiple daily administrations in research protocols to maintain pulsatile GH stimulation. [hkroids.com]

Key Peer-Reviewed & Scientific References

1. Raun K. et al. Ipamorelin and GHRH analog synergy in GH secretion. Eur J Endocrinol. 1998;139(5):552–561.
2. Jetté L. et al. Human growth hormone-releasing factor analogs and receptor activation. Endocrinology. 2005;146(7):3052–3058.
3. CJC-1295 No DAC: Mechanism & Research Applications [oathpeptides.com]
4. CJC-1295 DAC vs No DAC: Comparative Guide [hkroids.com]
5. Unlocking the Potential of CJC-1295 No DAC [medicalnewshome.com]